Particularly in breast cancer, genetic polymorphisms of proteins involved in drug transport or metabolism have been shown to affect the efficacy of agents such as tamoxifen, taxanes or aromatase inhibitors [7,33,34]. Here, CYP19A1 is linked to breast cancer.